NIH group accuses Lilly of manipulating guidelines

A group of top scientists at the NIH have accused Eli Lilly of orchestrating the creation of medical guidelines in order to push sales of its sepsis drug Xigris. And they add that the company is now lobbying to make the use of Xigris for sepsis a quality standard that would earn physicians who use the drug additional bonus funds. Senior NIH investigator Dr. Peter Q. Eichacker says that people deserve to see medical guidelines developed without the undue influence of the drug industry. And they warn that drug companies instead are using the guidelines as a powerful method for promoting products. A statement from Lilly said that the company did not believe that Lilly had played a role in creating the guidelines and that it had always been open about its funding of the initiative.

- check out the report on Lilly from The Boston Globe

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.